ACE 031 × 10 Vials

ACE-031, also known as ACVR2B or ActRIIB-IgG1, is a synthetically produced protein originally developed by two biopharmaceutical companies, Acceleron and Shire, for its potential ability to inhibit myostatin and other natural proteins that limit muscle growth. It was hypothesized that ACE-031 would act as a decoy receptor for catabolic proteins, particularly myostatin, and bind to them to keep them from forming muscle fibers. The study was designed to determine whether ACE-031 is an effective treatment for children with Duchenne muscular dystrophy (DMD).

Molecular Formula: C133H227N43O33
Molar Weight: 2956.5 g/mol
Protein Composition: Extracellular domain of human activin receptor type IIB (ActRIIB) fused to the Fc region of human IgG1
Protein Classification: Recombinant fusion protein; soluble decoy receptor
Purity: ≥ 99 % (HPLC / SEC, typical)
Appearance: White to off-white lyophilised powder
Storage: Desiccated, protected from light, stored at –20 °C
Solubility: Soluble in sterile water and buffered aqueous solutions